DE59808106D1 - Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe - Google Patents

Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe

Info

Publication number
DE59808106D1
DE59808106D1 DE59808106T DE59808106T DE59808106D1 DE 59808106 D1 DE59808106 D1 DE 59808106D1 DE 59808106 T DE59808106 T DE 59808106T DE 59808106 T DE59808106 T DE 59808106T DE 59808106 D1 DE59808106 D1 DE 59808106D1
Authority
DE
Germany
Prior art keywords
symptoms
disease
treatment
parkinson
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE59808106T
Other languages
English (en)
Inventor
Lothar Saiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE59808106D1 publication Critical patent/DE59808106D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE59808106T 1998-12-03 1998-12-09 Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe Expired - Fee Related DE59808106D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855704A DE19855704C2 (de) 1998-12-03 1998-12-03 Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
PCT/DE1998/003612 WO2000032232A1 (de) 1998-12-03 1998-12-09 Mittel zur behandlung der symptome der parkinsonschen krankheit enthaltend ein zusätzliches lokalanästhetikum

Publications (1)

Publication Number Publication Date
DE59808106D1 true DE59808106D1 (de) 2003-05-28

Family

ID=7889787

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19855704A Expired - Fee Related DE19855704C2 (de) 1998-12-03 1998-12-03 Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
DE59808106T Expired - Fee Related DE59808106D1 (de) 1998-12-03 1998-12-09 Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19855704A Expired - Fee Related DE19855704C2 (de) 1998-12-03 1998-12-03 Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit

Country Status (8)

Country Link
US (1) US6514999B1 (de)
EP (1) EP1154794B1 (de)
JP (1) JP2002531417A (de)
AT (1) ATE238067T1 (de)
DE (2) DE19855704C2 (de)
ES (1) ES2200403T3 (de)
HK (1) HK1042238A1 (de)
WO (1) WO2000032232A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011269A1 (de) * 2001-07-31 2003-02-13 Lothar Saiger Mittel zur behandlung der symptome von demenzerkrankungen enthalten ein zusatzliches lokalanasthetikum
JP2010536873A (ja) * 2007-08-22 2010-12-02 ネイサン・ディー・ザスラー 神経原性振戦を調節するための局所麻酔剤の新規適用
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
AU2019288490A1 (en) * 2018-06-21 2020-12-03 Nevada Research & Innovation Corporation Disease modifying methods for treating neurodegenerative diseases using nootropic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
MX9700850A (es) * 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
DE19626621A1 (de) 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
DE19716905C1 (de) 1997-04-22 1998-08-27 Iip Inst Fuer Ind Pharmazie Fo Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung

Also Published As

Publication number Publication date
DE19855704C2 (de) 2002-08-01
ATE238067T1 (de) 2003-05-15
EP1154794B1 (de) 2003-04-23
ES2200403T3 (es) 2004-03-01
JP2002531417A (ja) 2002-09-24
WO2000032232A1 (de) 2000-06-08
HK1042238A1 (en) 2002-08-09
DE19855704A1 (de) 2000-07-20
EP1154794A1 (de) 2001-11-21
US6514999B1 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
Weiss et al. Neurochemical mechanisms underlying stress-induced depression
Wang et al. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
Kim et al. Effect of acupuncture on behavioral hyperactivity and dopamine release in the nucleus accumbens in rats sensitized to morphine
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE271874T1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
ATE254172T1 (de) Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase
DE60333857D1 (de) Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
DE3751036T2 (de) Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen.
DE69426471T2 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
Ward et al. Modafinil facilitates performance on a delayed nonmatching to position swim task in rats
DE59808106D1 (de) Behandlung der symptome der parkinsonschen krankheit mit einem mittel enthaltend eine dopaminerge substanz und ein lokalanaesthetikum der anilid-gruppe
ATE4115T1 (de) 6-substituierte 11-alkylen-morphantridine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
ATE503474T1 (de) Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis
Archer et al. Delayed exercise-induced functional and neurochemical partial restoration following MPTP
DE59206036D1 (de) Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
Bellot et al. Repeated monosialoganglioside administration attenuates behavioral sensitization to amphetamine
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE304861T1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
CN104826005A (zh) 一种外用镇痛软膏及制配方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee